Sunitinib Efficacy Against Advanced Renal Cell Carcinoma

Motzer, 2000, Systemic therapy for renal cell carcinoma, J Urol, 163, 408, 10.1016/S0022-5347(05)67889-5 Motzer, 2004, Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma, J Clin Oncol, 22, 454, 10.1200/JCO.2004.06.132 Linehan, 2004, Genetic basis of cancer of the kidney: disease-specific approaches to therapy, Clin Cancer Res, 10, 6282S, 10.1158/1078-0432.CCR-050013 Kim, 2004, Role of VHL gene mutation in human cancer, J Clin Oncol, 22, 4991, 10.1200/JCO.2004.05.061 Mendel, 2003, In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship, Clin Cancer Res, 9, 327 Motzer, 2006, Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma, J Clin Oncol, 24, 16, 10.1200/JCO.2005.02.2574 Motzer, 2006, Sunitinib in patients with metastatic renal cell carcinoma, JAMA, 295, 2516, 10.1001/jama.295.21.2516 Therasse, 2000, New guidelines to evaluate the response to treatment in solid tumors, J Natl Cancer Inst, 92, 205, 10.1093/jnci/92.3.205 Motzer, 2007, Sunitinib versus interferon alfa in metastatic renal-cell carcinoma, N Engl J Med, 356, 115, 10.1056/NEJMoa065044 Motzer, 2002, Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma, J Clin Oncol, 20, 289, 10.1200/JCO.20.1.289 Motzer, 1999, Effect of cytokine therapy on survival for patients with advanced renal cell carcinoma, J Clin Oncol, 18, 1928, 10.1200/JCO.2000.18.9.1928 Hudes, 2006, A phase III, randomized, 3-arm study of temsirolimus (TEMSR) or interferon-alpha (IFN) or the combination of TEMSR + IFN in the treatment of first-line, poor-risk patients with advanced renal cell carcinoma (adv RCC), J Clin Oncol, 24, 930s, 10.1200/jco.2006.24.18_suppl.lba4 Yang, 2003, A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer, N Engl J Med, 349, 427, 10.1056/NEJMoa021491 Escudier, 2007, Sorafenib in advanced clear-cell renal-cell carcinoma, N Engl J Med, 356, 125, 10.1056/NEJMoa060655 Rini, 2007, Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib, J Natl Cancer Inst, 99, 81, 10.1093/jnci/djk008 Flanigan, 2001, Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal cell cancer, N Engl J Med, 345, 1655, 10.1056/NEJMoa003013 Mickisch, 2001, Tumor nephrectomy plus interferon alpha is superior to interferon alpha alone in metastatic renal cell carcinoma, Lancet, 358, 966, 10.1016/S0140-6736(01)06103-7 Rini, 2006, Patients with metastatic renal cell carcinoma with long-term disease-free survival after treatment with sunitinib and resection of residual metastases, Clin Genitourin Cancer, 5, 232, 10.3816/CGC.2006.n.042